{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:42:35Z","timestamp":1779320555779,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA076292"],"award-info":[{"award-number":["P30 CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00520-018-4120-6","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T16:32:47Z","timestamp":1521131567000},"page":"2911-2918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors"],"prefix":"10.1007","volume":"26","author":[{"given":"Sonam","family":"Puri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine Crowe","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita Y.","family":"Kinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daneng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"4120_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2354.2008.00994.x","volume":"18","author":"M Browall","year":"2009","unstructured":"Browall M, Persson LO, Ahlberg K, Karlsson P, Danielson E (2009) Daily assessment of stressful events and coping among post-menopausal women with breast cancer treated with adjuvant chemotherapy. Eur J Cancer Care 18:507\u2013516","journal-title":"Eur J Cancer Care"},{"key":"4120_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0885-3924(00)00249-9","volume":"21","author":"SD Passik","year":"2001","unstructured":"Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE (2001) The changeable nature of patients\u2019 fears regarding chemotherapy: implications for palliative care. J Pain Symptom Manag 21:113\u2013120","journal-title":"J Pain Symptom Manag"},{"key":"4120_CR3","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261","journal-title":"J Clin Oncol"},{"key":"4120_CR4","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392","journal-title":"Support Care Cancer"},{"key":"4120_CR5","first-page":"6831","volume":"37","author":"H Fujii","year":"2017","unstructured":"Fujii H, Iihara H, Kajikawa N, Kobayashi R, Suzuki A, Tanaka Y, Yamaguchi K, Yoshida K, Itoh Y (2017) Control of nausea based on risk analysis in patients with esophageal and gastric cancer who received cisplatin-based chemotherapy. Anticancer Res 37:6831\u20136837","journal-title":"Anticancer Res"},{"key":"4120_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14:141\u2013147","journal-title":"J Community Support Oncol"},{"key":"4120_CR7","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478","journal-title":"J Clin Oncol"},{"key":"4120_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497\u2013503","journal-title":"Support Care Cancer"},{"key":"4120_CR9","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.3747\/co.19.1074","volume":"19","author":"N Bouganim","year":"2012","unstructured":"Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M (2012) Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 19:e414\u2013e421","journal-title":"Curr Oncol"},{"key":"4120_CR10","first-page":"14","volume":"11","author":"G Dranitsaris","year":"2013","unstructured":"Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M (2013) Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Support Oncol 11:14\u201321","journal-title":"J Support Oncol"},{"key":"4120_CR11","doi-asserted-by":"crossref","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manag 47(5):839\u2013848","DOI":"10.1016\/j.jpainsymman.2013.06.012"},{"key":"4120_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711\u2013717","journal-title":"Cancer Sci"},{"key":"4120_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/pgs.10.67","volume":"11","author":"C Hammer","year":"2010","unstructured":"Hammer C, Fasching PA, Loehberg CR, Rauh C, Ekici AB, Jud SM, Bani MR, Beckmann MW, Strick R, Niesler B (2010) Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics 11:943\u2013950","journal-title":"Pharmacogenomics"},{"key":"4120_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.clinthera.2014.06.016","volume":"36","author":"H He","year":"2014","unstructured":"He H, Yin JY, Xu YJ, Li X, Zhang Y, Liu ZG, Zhou F, Zhai M, Li Y, Li XP, Wang Y, Zhou HH, Liu ZQ (2014) Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther 36:1242\u20131252 e1242","journal-title":"Clin Ther"},{"key":"4120_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11912-013-0312-x","volume":"15","author":"M Trammel","year":"2013","unstructured":"Trammel M, Roederer M, Patel J, McLeod H (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Current Oncol Rep 15:276\u2013285","journal-title":"Current Oncol Rep"},{"key":"4120_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clpt.2005.08.015","volume":"78","author":"MO Babaoglu","year":"2005","unstructured":"Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A (2005) Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 78:619\u2013626","journal-title":"Clin Pharmacol Ther"},{"key":"4120_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2133\/dmpk.DMPK-12-RG-084","volume":"28","author":"D Tsuji","year":"2013","unstructured":"Tsuji D, Kim YI, Nakamichi H, Daimon T, Suwa K, Iwabe Y, Hayashi H, Inoue K, Yoshida M, Itoh K (2013) Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab Pharmacokinet 28:299\u2013304","journal-title":"Drug Metab Pharmacokinet"},{"key":"4120_CR18","doi-asserted-by":"crossref","unstructured":"Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K (2017) Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J 17(5):435\u2013440","DOI":"10.1038\/tpj.2016.38"},{"key":"4120_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1188\/14.ONF.195-202","volume":"41","author":"SW Wesmiller","year":"2014","unstructured":"Wesmiller SW, Bender CM, Sereika SM, Ahrendt G, Bonaventura M, Bovbjerg DH, Conley Y (2014) Association between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery. Oncol Nurs Forum 41:195\u2013202","journal-title":"Oncol Nurs Forum"},{"key":"4120_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2217\/14622416.9.5.501","volume":"9","author":"B Niesler","year":"2008","unstructured":"Niesler B, Kapeller J, Hammer C, Rappold G (2008) Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 9:501\u2013504","journal-title":"Pharmacogenomics"},{"key":"4120_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-008-0387-1","volume":"134","author":"PA Fasching","year":"2008","unstructured":"Fasching PA, Kollmannsberger B, Strissel PL, Niesler B, Engel J, Kreis H, Lux MP, Weihbrecht S, Lausen B, Bani MR, Beckmann MW, Strick R (2008) Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol 134:1079\u20131086","journal-title":"J Cancer Res Clin Oncol"},{"key":"4120_CR22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","volume":"21","author":"PB Tremblay","year":"2003","unstructured":"Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21:2147\u20132155","journal-title":"J Clin Oncol"},{"key":"4120_CR23","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1200\/JCO.2002.09.064","volume":"20","author":"R Kaiser","year":"2002","unstructured":"Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805\u20132811","journal-title":"J Clin Oncol"},{"key":"4120_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","volume":"34","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical O (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381\u2013386","journal-title":"J Clin Oncol"},{"key":"4120_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JOP.2011.000397","volume":"7","author":"E Basch","year":"2011","unstructured":"Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 7:395\u2013398","journal-title":"J Oncol Pract"},{"key":"4120_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"4120_CR27","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89:1634\u20131646","journal-title":"Cancer"},{"key":"4120_CR28","unstructured":"U.S. Department of Health and Human Services (2010) Common terminology criteria for adverse events (CTCAE) version 4.03. In: editor (ed)^(eds) Book common terminology criteria for adverse events (CTCAE) version 4.03, City"},{"key":"4120_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/clpt.2011.287","volume":"91","author":"KR Crews","year":"2012","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321\u2013326","journal-title":"Clin Pharmacol Ther"},{"key":"4120_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0091270009359182","volume":"50","author":"S Borges","year":"2010","unstructured":"Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450\u2013458","journal-title":"J Clin Pharmacol"},{"key":"4120_CR31","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986\u20131992","journal-title":"Ann Oncol"},{"key":"4120_CR32","first-page":"W9","volume":"7","author":"T Petrella","year":"2009","unstructured":"Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G (2009) Identifying patients at risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool: II. Delayed nausea and vomiting support. Oncologia 7:W9\u2013W16","journal-title":"Oncologia"},{"key":"4120_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","volume":"2","author":"M Clemons","year":"2016","unstructured":"Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G (2016) Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2:225\u2013231","journal-title":"JAMA Oncol"},{"key":"4120_CR34","unstructured":"Center for Disease Control and Prevention (2017) Preventing infections in cancer patients. In: Editor (ed)^(eds) Book Preventing infections in cancer patients, City. URL: \n                    https:\/\/www.cdc.gov\/cancer\/preventinfections\/providers.htm\n                    \n                  . Accessed 21 June 2017"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4120-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4120-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4120-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T15:12:09Z","timestamp":1589641929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4120-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4120"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4120-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript describes original work and is not under consideration by any other journal. We have adhered to the journals submission requirements. We have full control of all primary data and we agree to allow the journal to review the data if requested. All authors approve the manuscript and its submission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Li is a consultant for Novartis. Dr. Jim is a consultant for RedHill Biopharma. This work was performed while Dr. Jacobsen was at the Moffitt Cancer Center and does not represent the views of the National Cancer Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by ant of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}